Hai-Dong Zhu

Dr. Hai-Dong Zhu


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2025 in Bioactive Materials
Verified
Journal Article
Open access
LZLinzhu Zhang
Linzhu Zhang
DWDi Wang
Di Wang
YLYiming Liu
Yiming Liu
NYNailin Yang
Nailin Yang
SSShumin Sun
Shumin Sun
HZHai-Dong Zhu
Hai-Dong Zhu
Pyroptosis is a critical process that triggers inflammatory responses and mitochondrial DNA (mtDNA) release, thereby activating the cGAS-STING pathway. However, tumor metabolism, particularly glycolysis, often suppresses immune activation. To address this, we developed GOCoF2, a self-amplifying pyroptosis-STING nanoadjuvant that integrates glucose oxidase (GOx) with cobalt fluoride (CoF2) nanoenzymes. This nanoadjuvant excelled in converting intratumoral H2O2 into reactive oxygen species (ROS), inducing cell pyroptosis. Its self-sustaining mechanism involved glucose depletion and continuous H2O2 generation, ensuring persistent catalytic activity. This metabolic manipulation and induction of oxidative stress significantly enhance pyroptosis in tumor cells. The released mtDNA subsequently activated the cGAS-STING pathway, with Co2+ further amplifying this effect. Notably, glucose-dependent TREX2 inhibition intensified cGAS-STING activation through metabolic regulation, leading to a strong immune response and tumor growth suppression. When combined with immune checkpoint blockade therapy, GOCoF2 significantly inhibited primary and distant tumor progression via systemic immune activation. Additionally, we formulated GOCoF2-lipiodol for transarterial embolization, which demonstrated superior efficacy in a rat model of orthotopic hepatocellular carcinoma. This study not only sheds light on the intricate relationship between tumor metabolism and immune regulation but also introduces a novel therapeutic approach for hepatocellular carcinoma.

28 August 2025 in Advanced Science
Verified
Journal Article
Open access
LZLinzhu Zhang
Linzhu Zhang
SSShumin Sun
Shumin Sun
DWDuo Wang
Duo Wang
NYNailin Yang
Nailin Yang
DWDi Wang
Di Wang
LCLiang Cheng
Liang Cheng
The strategic induction of pyroptosis, coupled with the targeted potentiation of cGAS‐STING activation, represents a promising immunostimulatory approach. Herein, an intelligent lactate‐depleting LOCoF 2 nanoreactor system is developed that orchestrated self‐amplifying pyroptosis induction and cGAS‐STING signaling potentiation for enhanced catalytic immunotherapy. This nanoplatform integrated cobalt fluoride (CoF 2 ) nanoparticles with lactate oxidase (LOx), endowing it with dual enzymatic capabilities. Therefore, the LOCoF 2 nanoreactor initially served as a pyroptosis activator, synergistically inducing pyroptosis in cancer cells by catalyzing the sequential generation of reactive oxygen species (ROS) while simultaneously inhibiting damage repair mechanisms. Subsequently, it functioned as an intelligent STING agonist to selectively detect pyroptosis‐released mitochondrial DNA (mtDNA) and augment the activation of the cGAS‐STING pathway. In vivo evaluations reveal that LOCoF 2 administration provoked robust antitumor immunity, with synergistic effects observed when combined with immune checkpoint inhibitors, leading to significant regression of both primary and distant lesions. Notably, the LOCoF 2 ‐lipiodol emulsion demonstrates exceptional therapeutic performance in a rat orthotopic hepatocellular carcinoma model when integrated with transcatheter arterial embolization (TAE) or transarterial chemoembolization (TACE) treatments. Therefore, the adverse factor lactate is ingeniously utilized to increase the activation of pyroptosis‐STING via a cascade reaction, ultimately achieving superior tumor control.

18 January 2026 in Medcomm
Verified
Journal Article
Open access
YFYan Fu
Yan Fu
ZGZhi‐Shan Ge
Zhi‐Shan Ge
QCQing‐Yue Cao
Qing‐Yue Cao
ZLZi‐Han Li
Zi‐Han Li
AZAn Zhang
An Zhang
GTGao-Jun Teng
Gao-Jun Teng
Cancer neuroscience has emerged as a transformative frontier in oncology research, focusing on the interplay between cancer cells and the nervous system. Cancer cells establish tumorspecific neural networks within tumor tissues via neurotrophic hijacking. The nervous system regulates tumor initiation, progression, and metastasis either directly by regulating signal transduction in tumor cells or indirectly by modulating the tumor microenvironment (TME). The positive feedback loop between cancer cells and nerves promotes tumor progression. Deciphering the regulatory role of nerves in tumor progression may yield novel anticancer therapeutic options. In this review, the interaction between nerves and cancer cells is described, including how cancer cells hijack and remodel nervous system structure and function, and how neuron‐signaling regulates cancer cell growth directly or indirectly through modulating the TME. This evidence of the critical role of nerves in the malignant phenotype of tumors indicates the potential of using neuron‐signaling targeting strategies in cancer treatment. By summarizing these findings, this review aims to provide comprehensive insights into the interaction between nerves and cancer cells, paving the way for neuron‐signaling‐based anticancer therapies.

1 September 2024 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
LZLin-Zhu Zhang
Lin-Zhu Zhang
RDRui-Jie Du
Rui-Jie Du
DWDuo Wang
Duo Wang
JQJuan Qin
Juan Qin
CYChao Yu
Chao Yu
HZHai-Dong Zhu
Hai-Dong Zhu
With the in-depth knowledge of the pathological and physiological characteristics of the intestinal barrier–portal vein/intestinal lymphatic vessels–systemic circulation axis, oral targeted drug delivery is frequently being renewed. With many advantages, such as high safety, convenient administration, and good patient compliance, many researchers have begun to explore targeted drug delivery from intravenous injections to oral administration. Over the past few decades, the fields of materials science and nanomedicine have produced various drug delivery platforms that hold great potential in overcoming the multiple barriers associated with oral drug delivery. However, the oral transport of particles into the systemic circulation is extremely difficult due to immune rejection and biochemical invasion in the intestine, which limits absorption and entry into the bloodstream. The feasibility of the oral delivery of targeted drugs to sites outside the gastrointestinal tract (GIT) is unknown. This article reviews the biological barriers to drug absorption, the in vivo fate and transport mechanisms of drug carriers, the theoretical basis for oral administration, and the impact of carrier structural evolution on oral administration to achieve this goal. Finally, this article reviews the characteristics of different nano-delivery systems that can enhance the bioavailability of oral therapeutics and highlights their applications in the efficient creation of oral anticancer nanomedicines.

31 July 2026 in Hepatoma Research
Verified
Journal Article
Open access
PDF file
YMYu-Yan Ma
Yu-Yan Ma
LCLi Chen
Li Chen
CLCheng-Hui Li
Cheng-Hui Li
YLYue-Yong Li
Yue-Yong Li
GLGuo-Jun Li
Guo-Jun Li
HZHai-Dong Zhu
Hai-Dong Zhu
Transarterial chemoembolization (TACE) is an important treatment for intermediate-stage hepatocellular carcinoma (HCC) that often needs to be repeated. However, the optimal number of treatments remains unclear, and the relationship between repeated TACE and patient prognosis is complex and needs to be systematically investigated. Evidence shows that the initial efficacy of TACE is significant; however, with an increase in the number of treatments, the objective response rate of the tumor decreases, and TACE-related liver injury accumulates, which becomes a key factor restricting the long-term survival of patients with HCC. In recent years, the new paradigm of TACE combined with targeted therapy plus immunotherapy has shown significant advantages, improving the tumor remission rate, reducing the number of TACE required, and protecting liver function. In terms of prognosis prediction, the model is evolving from a static model based on baseline characteristics to a dynamic model that integrates treatment response. Frontier research has further explored prognostic prediction models based on genomics, radiomics, and machine learning, providing a direction for achieving higher accuracy of individualized prognostic prediction. This narrative review aims to synthesize the current evidence, explore the relationship between the number of TACE treatments and the prognosis of HCC patients, compare TACE alone versus TACE combined with systemic therapy, and review the methodological progress of prognosis-prediction models.